Clinical Trials
2 trialsNCT00390455 2019-12-20
Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
National Cancer Institute (NCI)
Phase 3 Completed
NCT00688194 2013-08-26
Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
National Cancer Institute (NCI)
Phase 3 Unknown